Variable | Norovirus cases (n = 72) n (%); median [IQR] | Controls (n = 72) n (%); median [IQR] | p-value |
---|---|---|---|
Demographic features | |||
Age at the time of KT (years) | 46 [33.7–58.7] | 46 [34–58.1] | 0.83 |
Male sex | 39 (54.2) | 37 (51.4) | 0.74 |
Primary kidney disease | 0.08 | ||
Diabetic | 15 (20.8) | 7 (9.7) | |
Vascular | 11 (15.3) | 13 (18.1) | |
Chronic glomerulonephritis | 11 (15.3) | 19 (26.4) | |
Others | 35 (48.6) | 33 (45.8) | |
Diabetes | |||
Before transplantation | 20 (27.8) | 7 (9.7) | 0.01 |
NODAT | 4 (5.8) | 5 (6.9) | 1 |
Characteristics of KT | |||
c-PRA | 30.1 | 30.2 | 0.88 |
First Transplantation | 65 (90.3) | 61 (84.7) | 0.8 |
Deceased donor | 61 (84.7) | 60 (83.3) | 1 |
Duration of dialysis (months) | 28 [7–66] | 24 [9–54] | 0.24 |
HLA mismatch | 0.97 | ||
< 2 | 11 (15.7) | 10 (14.1) | |
≥ 3 | 61 (84.3) | 62 (85.9) | |
Induction therapy | |||
ATG | 70 (97) | 67 (93) | 0.55 |
Basiliximab | 2 (3) | 5 (7) | 0.21 |
Maintenance therapy | |||
Dual therapy | 29 (40.3) | 30 (41.7) | 1 |
Triple therapy | 89.5 [68–118] | 92 [72–123] | 0.42 |
Events between KT and NoV diagnosis (or index date) | |||
Plasma CMV reactivation | 14 (20) | 10 (14.1) | 0.38 |
Other OI a | 5 (7) | 1 (1.4) | 0.12 |
Data recorded at diagnosis | |||
Immunosuppressive regimen | |||
Corticosteroid | 43 (59.7) | 42 (58.3) | 1 |
Mycophenolic acid | 68 (94.4) | 67 (93.1) | 1 |
Tacrolimus | 43 (59.7) | 39 (54.2) | 0.61 |
Ciclosporin | 21 (29.2) | 31 (43.1) | 0.05 |
Laboratory data at diagnosis | |||
Serum creatinine level (μM) | 139 [105–169] | 135 [91–172] | 0.95 |
eGFR (ml/min/1.73m2) | 47 [41–65] | 47 [38–68] | 0.79 |
Positive CMV PCR | 10 (13.8) | 6 (8.3) | 0,06 |
Gamma-globulin < 6.5 g/L | 10 (13.9) | 4 (5.6) | 0.06 |
Lymphocyte count (/mm3) | 500 [300–840] | 875 [665–1430] | 0.01 |